On September 20, 2024, the Centers for Medicare & Medicaid Services (CMS) released the long-awaitedfinal ruleaddressing several important drug pricing matters under the Medicaid Drug Rebate Program (MDRP) (Final Rule). The Final Rule’s provisions also have significant ...
CMS Proposes ACA Medicaid Drug Pricing RuleRogers, Daniel R
The $2 Drug List Model could have a limited impact on manufacturers of generic drugs, as it would primarily focus on drugs already on lower-cost formulary tiers. However, the model could affect the market share and competition among generic drugs as well as t...
Healthcare Life Sciences Drug Pricing Digest - May 2025 Latham & Watkins LLP on 5/6/2025 Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law...more Court Strikes Down FDA Rule...
Revert 340B hospital reimbursement from average sales price (ASP) minus 22.5 percent to ASP plus 6 percent, following the U.S. Supreme Court's June 15 decision, and consistent with the proposed rule. To maintain budget neutrality, all nondrug services for CY 2023 will receive ...
CMS proposes payment of drugs at an adjusted payment level representing the frequency with which the study drug and placebo (or comparator) is furnished. The base payment amount for the study drug is proposed to be ASP + 6 percent. If no ASP data is available, then CMS proposes to pay...
McCurdy, Debra
Drugmakers who submit incomplete quarterly and monthly pricing data could face monetary penalties or be terminated from the drug rebate program by CMS, the agency says in response to a report chastising it for failing to take action against noncompliant drugmakers.LaCrisha Butler...
Ankur J. Goel